It’s our focus on quality, innovative design, and processing that sets Ventris® apart from the competition. Ventris® controls the supply chain – from the origin of the material all the way through to its clinical application.
Ventris® offers a broad variety of allograft, synthetic, and bioactive products for soft and hard tissue applications. We design, develop, and market best in class products for optimal surgical outcomes and level of patient care.
Our line of human allograft products is regulated by the FDA Center for Biologics Evaluation and Research (CBER), which regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps). Ventris® adheres to Current Good Tissue Practices, focusing extensively on donor eligibility and the recovery process. Ventris® Allograft products are regulated under 21 CFR Part 1270 and 21 CFR Part 1271 and Section 361 of the Public Health Services Act. The company is dedicated to providing products that adhere to the strictest current tissue banking and processing standards, with the ultimate goal of an exceptional outcome for the patient.